UA131131U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis involves clinical examination and radiography. Additionally, serum MTHFR C67P polymorphism, CISR content, homocysteine, IL-6, SRP, and homozygous carrier 677-TT and SISP levels <102 ng / ml, homocysteine> 20 μmol / l, IL-6, IL-6, are determined in serum. / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M.: Med. lit., 2001. - Vol. 2. - P. 186-196).

The disadvantage of these methods is the inability to predict the dynamics of the process in the early subclinical stages, the inability to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the methylenetetrahydrofolate reductase gene (MINEV Sb677T), the content of the C-terminal propeptide of collagen type (SICP), homocysteine, interleukin b (IL-b6) is determined in the patient's blood serum. , C-reactive protein (SRP), and with homozygous carrier 677-HT, the content of SISR "102 ng/ml, homocysteine 220 μmol/l, 1L-6 "10 ng/l, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are performed, and the MTNEV C677T gene polymorphism is determined. The content is determined by the immunoenzymatic method

SISR, homocysteine, IL-6, SRP. With homozygous carrier 677-TT, levels of SISR "102 ng/ml, homocysteine 220 μmol/l, IL-6 "10 ng/l, SRP "6 mg/l predict the development of osteoarthritis.

A specific example of using the method

Patient G., 56 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of SISR, homocysteine, IL-6, and SRP was determined by the immunoenzymatic method. Homozygous carrier 677-TT was established.

Levels of SISR - 86 ng/ml, homocysteine - 29 μmol/l, IL-6-18 ng/l, SRP - 14 mg/l. The development of osteoarthritis was diagnosed. After 13 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which differs in that the polymorphism of the MTNEV C67P gene, the content of SICR, homocysteine, IL-6, SRP are additionally determined in the blood serum, and in case of homozygous carrier 677-171 and levels of SICR 102 ng/ml, homocysteine 220 μmol/l, IL-6 »10 ng/l, SRP »b mg/l predict the development of osteoarthritis.